한글 Creating therapeutic opportunities for the most serious diseases.

Founded in 2017, MediMabBio stands at the forefront of groundbreaking advancements in the field of immuno-oncology. Our company is dedicated to transforming the landscape of cancer treatment through the innovative development of protein therapeutics, including therapeutic antibodies and fusion proteins. With a relentless commitment to scientific excellence, we’re poised to redefine the future of cancer therapy by leveraging rational design principles that drive the initial discovery of our exceptional drug candidates.

Collaboration for Impact

Collaborative spirit is at the core of everything we do. Firmly placing ourselves in the open innovation philosophy, we actively engage with the global scientific community to source opportunities for groundbreaking discoveries. By pooling expertise and resources, we accelerate the pace of discovery and development, moving closer to solving the greatest health challenges.

Research collaborations

University of Oxford

University of Oxford

University of Birmingham

University of Birmingham

KAIST

KAIST

아산재단

아산재단

Bio Escalator

Bio Escalator

CXOs

Patheon

Patheon

Charles River

Charles River

Company History

2023

2022

  • Received the “Excellent Workspace Innovation” award by the Ministry of Employment and Labor
  • Recognized as “Excellent Employer for Young People” by the Seongnam City Council

2021

  • CDMO partnership
  • R&D partnership
  • Series A $14M

2020

  • MediMab Biotherapeutics (UK Subsidiary) Established

2019

  • Pre-Series A $2.3M

2017-18

  • Selected for TIPS Investment
  • MediMabBio Founded